Approved Hospital Formulary
Add Formweb to your mobile device
Medications not yet evaluated by P&T are considered NON-FORMULARY. Always check 2 unique patient identifiers - NAME and DATE OF BIRTH - at every step!
Please be sure to document all clinical activities daily.
Please be sure to document all clinical activities daily.
Approved Hospital Formulary
Search results for:
daunorubicin liposomal-cytarabine liposomal
daunorubicin liposomal-cytarabine liposomal
- Restricted Vyxeos --> restricted to oncology.
Last updated: Mar. 5, 2025
- Black Box Warning: Do Not Interchange with other Daunorubicin and/or Cytarabine Containing Products
- HAZ-MED: Table 1 (daunorubicin liposomal)
- HAZ-MED: Table 1 (cytarabine liposomal)
- Formulary, Not Routinely Stocked: Vyxeos --> 44 mg-100 mg
Vyxeos is restricted to oncology. Inpatient therapy recommended for induction phase, due to potential tumor lysis, strict monitoring, and need for transfusions, and in consolidation phase in patients that require hospitalization during that phase. Available for outpatient infusions during consolidation phase.
Reviewed: 24 July 2018 (Vyxeos)